SCHEDULE: Vanguard Group Reports 0% Stake in Ginkgo Bioworks

The Vanguard Group has filed an amended Schedule 13G, indicating a 0% beneficial ownership in Ginkgo Bioworks Holdings Inc. following an internal realignment.

Summary

• The Vanguard Group filed an Amendment No. 5 to Schedule 13G regarding its beneficial ownership in Ginkgo Bioworks Holdings Inc. Common Stock.
• As of March 13, 2026, The Vanguard Group reports 0% beneficial ownership of Ginkgo Bioworks Holdings Inc. Common Stock.
• This change is attributed to an internal realignment at The Vanguard Group, Inc. on January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions of The Vanguard Group, Inc. will now report beneficial ownership separately (on a disaggregated basis).
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by these disaggregated subsidiaries and/or business divisions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. It primarily reflects an administrative change in The Vanguard Group's reporting structure and does not convey new information about Ginkgo Bioworks' operational performance or The Vanguard Group's overall investment sentiment towards the company.

Positives

• The internal realignment by The Vanguard Group may lead to more granular and specific reporting of beneficial ownership by its individual subsidiaries, potentially enhancing transparency for specific funds or investment strategies.

Negatives

• Investors seeking to understand The Vanguard Group's aggregate holdings in Ginkgo Bioworks Holdings Inc. may now need to track multiple separate filings from its various subsidiaries, rather than relying on a single consolidated report from the parent entity.

Risks

• No specific risks related to Ginkgo Bioworks Holdings Inc. are mentioned in this filing, as it primarily concerns The Vanguard Group's internal reporting structure.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding Ginkgo Bioworks Holdings Inc.'s operations or The Vanguard Group's future investment strategies beyond the described reporting realignment.

Industry Context

StockSavvy.ai notes that institutional investors like The Vanguard Group periodically undertake internal reorganizations that impact their reporting of beneficial ownership. This realignment reflects an administrative adjustment in how Vanguard's various investment arms disclose their holdings, rather than a change in investment thesis or a direct divestment from Ginkgo Bioworks by all Vanguard-managed funds. Such changes are typically driven by internal operational efficiencies or evolving regulatory interpretations.

Corporate Governance

Stakeholder Impact

• Shareholders of Ginkgo Bioworks Holdings Inc. may need to monitor filings from individual Vanguard subsidiaries to gain a comprehensive understanding of The Vanguard Group's collective investment in the company.
• Investors in Vanguard funds may experience a change in how beneficial ownership is reported for specific funds, potentially offering more direct insight into individual fund holdings.

Key Dates

Recommendation

This filing is an administrative update from The Vanguard Group regarding its internal reporting structure and does not provide new information about Ginkgo Bioworks Holdings Inc.'s financial performance, strategic direction, or any change in investment thesis. Therefore, it does not warrant a change in investment recommendation for Ginkgo Bioworks, maintaining a 'hold' stance based solely on the content of this filing.

Keywords

Vanguard Group, Ginkgo Bioworks, Schedule 13G, Beneficial Ownership, Institutional Investor, SEC Filing, Common Stock, Realignment